ClinicalTrials.gg
CompletedNCT05573230Updated May 26, 2026Results posted

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

A Phase 1 interventional study of Midazolam and LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants. The study will also evaluate the safety and tolerability of LY3502970 in healthy participants. This study will last up to approximately 76 days for each participant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Participants with a body weight of 45 kilograms (kg) or more and (BMI) within the range of 18.5 to 35.0 kilograms per meter squared (kg/m²)
  • Participants who have a level of at least 11.4 grams/deciliter (g/dL) for female participants and at least 12.5 g/dL for male participants
  • Male participants who agree to use highly effective/effective methods of and female participants not of

Exclusion criteria

Exclusion Criteria:

  • Participants who have a significant history of or current cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Participants who regularly use known drugs of abuse
  • Women who are lactating and who are of
  • Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Midazolam + LY3502970

    Period 1: 200 micrograms (μg) midazolam administered as oral solution (5mg/5 mL solution ampoule) on Day -1 followed by 3 milligrams (mg) LY3502970 capsule given orally on Day 1.

    Drug: Midazolam · Drug: LY3502970

  • Experimental
    Cyclosporine + Midazolam + LY3502970

    Period 2: 2 -100 mg Cyclosporine capsules administered twice daily (BID) on Days 15 through 19; 3 mg LY3502970 given orally on Day 17; 200 μg Midazolam administered as oral solution on Days 16 and 19; Single oral dose 200 mg cyclosporine on Day 20.

    Drug: Midazolam · Drug: LY3502970 · Drug: Cyclosporine

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970

    PK: AUC of LY3502970

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose

  2. PK: Maximum Observed Concentration (Cmax) of LY3502970

    PK: Cmax of LY3502970

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose

07

Results

Posted May 26, 2026

Participant flow

This is a 2-period single arm study with a washout period of at least 14 days between Period 1 and Period 2.

Midazolam + LY3502970 (Period 1)
Participant flow — Midazolam + LY3502970 (Period 1)
MilestoneMidazolam + Cyclosporine + LY3502970
Started32
Received at least one dose of study drug31
Completed25
Not completed7
Withdrew: Adverse event4
Withdrew: Withdrawal by subject1
Withdrew: Physician decision2
Cyclosporine + LY3502970 (Period 2)
Participant flow — Cyclosporine + LY3502970 (Period 2)
MilestoneMidazolam + Cyclosporine + LY3502970
Started25
Completed21
Not completed4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970

PK: AUC of LY3502970

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose
Reported as:
Geometric mean · nanogram * hour per milliliter (ng*hr/mL
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970
nanogram * hour per milliliter (ng*hr/mLLY3502970 (Reference)Cyclosporine + LY3502970 (Test)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970332 ± 39857 ± 51
Statistical analysis
  • LY3502970 (Reference) vs Cyclosporine + LY3502970 (Test) · Mixed Models Analysis · Geometric ls mean ratio: 2.55 · 90% CI 2.07 to 3.14
PrimaryPK: Maximum Observed Concentration (Cmax) of LY3502970

PK: Cmax of LY3502970

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970
nanogram per milliliter (ng/mL)LY3502970 (Reference)Cyclosporine + LY3502970 (Test)
PK: Maximum Observed Concentration (Cmax) of LY350297013.9 ± 4818.4 ± 36
Statistical analysis
  • LY3502970 (Reference) vs Cyclosporine + LY3502970 (Test) · Mixed Models Analysis · Geometric ls mean ratio: 1.29 · 90% CI 1.00 to 1.66

Adverse events

Collected over Baseline up to 76 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 ug Midazolam0/31 (0%)0/31 (0%)4/31 (12.9%)
3 mg LY3502970 (Reference)0/31 (0%)0/31 (0%)28/31 (90.3%)
200 mg Cyclosporine BID + 200 ug Midazolam0/24 (0%)0/24 (0%)18/24 (75%)
200 mg Cyclosporine BID + 3 mg LY3502970 (Test)0/24 (0%)0/24 (0%)22/24 (91.7%)
200 mg Cyclosporine0/25 (0%)0/25 (0%)20/25 (80%)
Most frequent other events
Showing 10 of 22
Most frequent other events
Event200 ug Midazolam3 mg LY3502970 (Reference)200 mg Cyclosporine BID + 200 ug Midazolam200 mg Cyclosporine BID + 3 mg LY3502970 (Test)200 mg Cyclosporine
VomitingGastrointestinal disorders0/3113/311/2413/245/25
Decreased appetiteMetabolism and nutrition disorders0/315/310/2411/243/25
Abdominal distensionGastrointestinal disorders1/3111/310/2410/241/25
NauseaGastrointestinal disorders0/3111/312/249/241/25
Feeling hotGeneral disorders0/310/313/240/248/25
Catheter site bruiseGeneral disorders0/315/314/240/245/25
Catheter site swellingGeneral disorders0/310/314/241/242/25
HeadacheNervous system disorders1/315/312/244/244/25
DizzinessNervous system disorders0/315/311/242/240/25
Catheter site phlebitisGeneral disorders0/311/311/243/244/25

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Midazolam + Cyclosporine + LY3502970
Mean41.3 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Midazolam + Cyclosporine + LY3502970
Female4
Male27
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Midazolam + Cyclosporine + LY3502970
American Indian or Alaska Native0
Asian31
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Midazolam + Cyclosporine + LY3502970
Singapore31
08

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jan 2023, 3 months.

Results were first posted in May 2026, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Oct 10, 2022
StartActual
Oct 17, 2022
Primary completionActual
Jan 17, 2023
CompletionActual
Jan 17, 2023
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05573230
Responsible party
Sponsor
First posted
Oct 10, 2022
Start date
Oct 17, 2022
Primary completion
Jan 17, 2023
Completion
Jan 17, 2023
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion